Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Global Standard Drugs to Be Covered by Special Medical Expenditure System during Application
December 1, 2003
- BUSINESS NEWS IN BRIEF
December 1, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 24, 2003
- Kirin Preparing for Fully Independent Marketing from 2005
November 24, 2003
- MEDICAL DEVICE NEWS IN BRIEF
November 24, 2003
- 9-month Business Results
November 24, 2003
- DIAGNOSTIC NEWS IN BRIEF
November 24, 2003
- Toyama Chemical: Business Hit by Delay in TTP's Marketing Activities
November 24, 2003
- OTC NEWS IN BRIE
November 24, 2003
- Taisho: Synergistic Effect of Integration Not Yet Seen
November 24, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 24, 2003
- Santen: Overall Sales Down Slightly from Sluggish Domestic Sales
November 24, 2003
- Statement on Proper Use of Iressa Issued by JLCS
November 24, 2003
- Ono: Sales Increase 2.8%, Profits Up 3.9%
November 24, 2003
- Micardis Exerts Hypotensive Effects for 24-hour: JSH Meeting
November 24, 2003
- Dainippon: Rapid Drop in Sales of Gatiflo Hurts Sales, Profits
November 24, 2003
- Home Blood Pressure GL Compiled by JSH
November 24, 2003
- Tanabe Seiyaku: 9.7% Increase in Net Profits Despite Sales Drop
November 24, 2003
- NEW PRODUCTS
November 24, 2003
- Shionogi: Sales Plunge 44.3%, but Profits Up
November 24, 2003
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…